Humacyte Inc
HUMA
NASDAQ
Biotechnology
$0.60
USD
+0.05 (+9.96%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $148.30M
Volume 33.0M
Revenue
$2.12M
TTM
+159.3%
YoY
Gross Margin
-495%
TTM
-983.3%
YoY
Net Income
$-96.73M
TTM
-64.9%
YoY
Operating Cash Flow
$-97.19M
TTM
+7.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.3 | 0.8 | 0.5 | 0.5 | 0.4 |
YoY Growth | — | — | — | -4.3% | +34.9% |
Cost of Revenue | 0.2 | 0.3 | 9.1 | 2.0 | 1.2 |
Gross Profit | 0.1 | 0.5 | -8.6 | -1.5 | -0.8 |
Selling, General & Administrative | 7.8 | 7.6 | 7.6 | 7.9 | 8.0 |
Other Operating Expenses | 5.5 | 0.0 | 0.0 | 0.0 | 2.7 |
Total Operating Expenses | 35.3 | 24.9 | 22.2 | 27.4 | 28.9 |
Operating Income | -35.2 | -24.4 | -30.8 | -28.9 | -29.7 |
EBITDA | -33.9 | -21.5 | -31.1 | -27.6 | -28.4 |
Other Income / Expense | -0.7 | 8.9 | 8.6 | 13.3 | -5.2 |
Total Other Income / Expense | -2.5 | 6.9 | 6.0 | 11.3 | -7.1 |
Income Before Income Taxes | -37.7 | -17.5 | -24.8 | -17.6 | -36.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -37.7 | -17.5 | -24.8 | -17.6 | -36.8 |
Consolidated Net Income / Loss | -37.7 | -17.5 | -24.8 | -17.6 | -36.8 |
Net Income Attributable to Common Shareholders | -37.7 | -17.5 | -24.8 | -17.6 | -36.8 |
Basic EPS | -$0.24 | -$0.11 | -$0.13 | -$0.09 | -$0.16 |
Diluted EPS | -$0.24 | -$0.11 | -$0.13 | -$0.09 | -$0.16 |
Basic Shares Outstanding | 155.4M | 158.3M | 187.4M | 197.8M | 234.2M |
Diluted Shares Outstanding | 155.4M | 158.3M | 187.1M | 197.8M | 234.2M |